GITTO, STEFANO
 Distribuzione geografica
Continente #
NA - Nord America 5.826
EU - Europa 3.898
AS - Asia 3.606
SA - Sud America 827
Continente sconosciuto - Info sul continente non disponibili 169
AF - Africa 101
OC - Oceania 27
Totale 14.454
Nazione #
US - Stati Uniti d'America 5.665
RU - Federazione Russa 1.313
IT - Italia 1.273
SG - Singapore 957
CN - Cina 915
BR - Brasile 668
HK - Hong Kong 490
VN - Vietnam 433
PL - Polonia 337
KR - Corea 334
IE - Irlanda 281
SE - Svezia 162
FI - Finlandia 160
FR - Francia 122
BD - Bangladesh 115
IN - India 92
CA - Canada 89
DE - Germania 76
JO - Giordania 64
AR - Argentina 59
GB - Regno Unito 59
ID - Indonesia 56
EC - Ecuador 29
NL - Olanda 29
IQ - Iraq 28
JP - Giappone 27
MX - Messico 27
AU - Australia 26
PY - Paraguay 20
ZA - Sudafrica 17
PK - Pakistan 15
UA - Ucraina 15
CH - Svizzera 14
ES - Italia 14
CO - Colombia 13
CI - Costa d'Avorio 12
NG - Nigeria 12
KE - Kenya 11
UZ - Uzbekistan 11
VE - Venezuela 11
CL - Cile 10
MA - Marocco 10
TR - Turchia 10
PH - Filippine 9
RO - Romania 9
SA - Arabia Saudita 9
CR - Costa Rica 8
JM - Giamaica 8
EG - Egitto 7
PE - Perù 7
UY - Uruguay 7
AE - Emirati Arabi Uniti 6
DZ - Algeria 6
NP - Nepal 6
BJ - Benin 5
MY - Malesia 5
PR - Porto Rico 5
CZ - Repubblica Ceca 4
PT - Portogallo 4
SV - El Salvador 4
BO - Bolivia 3
CG - Congo 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
GT - Guatemala 3
HN - Honduras 3
HU - Ungheria 3
IL - Israele 3
KZ - Kazakistan 3
LB - Libano 3
NO - Norvegia 3
OM - Oman 3
PA - Panama 3
TG - Togo 3
TN - Tunisia 3
AM - Armenia 2
AT - Austria 2
AZ - Azerbaigian 2
BB - Barbados 2
BY - Bielorussia 2
DK - Danimarca 2
LT - Lituania 2
NI - Nicaragua 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
TH - Thailandia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
BE - Belgio 1
BF - Burkina Faso 1
BG - Bulgaria 1
BS - Bahamas 1
BZ - Belize 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
EU - Europa 1
GA - Gabon 1
GD - Grenada 1
GN - Guinea 1
Totale 14.272
Città #
Santa Clara 1.455
Ashburn 799
Singapore 744
Hong Kong 415
Fairfield 355
Warsaw 332
Seoul 331
Hefei 299
Dublin 280
Milan 254
San Jose 245
Ho Chi Minh City 173
Council Bluffs 148
Woodbridge 142
Lawrence 134
Seattle 131
Rome 123
Helsinki 119
Houston 116
Altamura 112
Cambridge 112
Florence 105
Beijing 104
Los Angeles 100
Chandler 82
Wilmington 82
Moscow 80
Hanoi 78
Lauterbourg 71
Boston 70
Princeton 67
Dallas 65
Buffalo 64
New York 64
The Dalles 62
São Paulo 56
Mumbai 53
Naples 45
Ann Arbor 43
Phoenix 42
Boardman 41
Jakarta 38
San Diego 38
Bologna 37
Kent 37
Lappeenranta 33
Shanghai 31
Munich 28
Melbourne 25
Figino 23
Redondo Beach 23
Tokyo 23
Toronto 23
Turin 23
Chicago 21
Da Nang 20
Frankfurt am Main 19
London 19
Medford 16
Brasília 15
Norwalk 15
Denver 14
Dong Ket 14
Bengaluru 13
Genoa 13
Miano 13
Rio de Janeiro 13
Abidjan 12
Brooklyn 12
Orem 12
Palermo 12
Paris 12
Porto Alegre 12
Quito 12
Abuja 11
Asunción 11
Bern 11
Haiphong 11
Thái Bình 11
San Francisco 10
West Jordan 10
Yubileyny 10
Amman 9
Atlanta 9
Baghdad 9
Bari 9
Belo Horizonte 9
Catania 9
Chennai 9
City of London 9
Clifton 9
Falls Church 9
Hillsboro 9
Montreal 9
Nairobi 9
Tashkent 9
Timisoara 9
Can Tho 8
Charlotte 8
Guangzhou 8
Totale 9.108
Nome #
Transjugular Intrahepatic Portosystemic Shunt does not affect the efficacy and safety of direct-acting antivirals in patients with advanced cirrhosis: A real-life, case-control study 315
Under-dilated TIPS Associate With Efficacy and Reduced Encephalopathy in a Prospective, Non-randomized Study of Patients With Cirrhosis 273
Low molecular weight heparin does not increase bleeding and mortality post-endoscopic variceal band ligation in cirrhotic patients 234
Adherence to Mediterranean diet in liver transplant recipients: a cross-sectional multicenter study 233
Quality of life in liver transplant recipients during the Corona virus disease 19 pandemic: A multicentre study 230
Altered clot formation and lysis are associated with increased fibrinolytic activity in ascites in patients with advanced cirrhosis 219
Transjugular intrahepatic portosystemic shunt (TIPS): current indications and strategies to improve the outcomes 214
Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: A validated prediction model 209
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment 193
The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes 191
Portosystemic shunt is an effective treatment for complications of portal hypertension in hepatic myeloid metaplasia and improves nutritional status 189
Alcohol use disorder and liver transplant: new perspectives and critical issues 184
Assessment of Liver Fibrosis With Elastography Point Quantification vs Other Noninvasive Methods 182
Characterization of lymphocyte subsets in ascitic fluid and peripheral blood of decompensated cirrhotic patients with chronic hepatitis C and alcoholic liver disease: A pivotal study 178
End-procedural adherence to recommended hemodynamic targets does not improve the outcome of elective tips in cirrhotic patients 174
Oxidative stress–induced fibrinogen modifications in liver transplant recipients: unraveling a novel potential mechanism for cardiovascular risk 171
Alcohol and viral hepatitis: A mini-review 170
Hepatitis C virus recurrence after liver transplantation: A 10-year evaluation 169
Alcohol associated liver disease 2020: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF) 168
Bioelectrical impedance vector analysis and cardiovascular performance in liver-transplanted recipients 165
Cellular and molecular mechanisms underlying liver fibrosis regression 164
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals. 163
Treatment of nonalcoholic steatohepatitis in adults: Present and future 160
The changing scenario of hepatocellular carcinoma in Italy: an update 160
Transjugular intrahepatic Porto-systemic shunt positively influences the composition and metabolic functions of the gut microbiota in cirrhotic patients 160
La prospettiva psicosomatica nella clinica dei trapianti d'organo. 154
Oncostatin M: From Intracellular Signaling to Therapeutic Targets in Liver Cancer 152
Predictors of solid extra-hepatic non-skin cancer in liver transplant recipients and analysis of survival: a long-term follow-up study 152
Super-resolution microscopy reveals an altered fibrin network in cirrhosis: The key role of oxidative stress in fibrinogen structural modifications 152
Pattern of macrovascular invasion in hepatocellular carcinoma 151
Alcoholic and Nonalcoholic Liver Disease: Diagnostic Assessment and Therapeutic Perspectives 150
Serum hepatitis B core-related antigen is an effective tool to categorize patients with HBeAg-negative chronic hepatitis B. 148
Unsupervised Exercise Intervention vs. Adherence to a Mediterranean Diet Alone: The Role of Bioelectrical Impedance Vector Analysis and Cardiovascular Performance in Liver-Transplanted Recipients 147
Needs evaluation questionnaire for liver disease: a novel assessment of unmet needs in patients with chronic liver disease 147
Cryptogenic cholestasis in young and adults: ATP8B1, ABCB11, ABCB4, and TJP2 gene variants analysis by high-throughput sequencing 145
Relevance of Spontaneous Portosystemic Shunts Detected with CT in Patients with Cirrhosis 143
Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis 143
Impact of hepatitis C virus infection on health-related quality of life before and after liver transplantation: a multidisciplinary point of view 143
Hepatic barrage to high-flow, intra-hepatic arteroportal fistulas requiring combined interventional approach 141
Non-alcoholic fatty liver disease and metabolic syndrome after liver transplant 138
Pre-transplant diabetes predicts atherosclerotic vascular events and cardiovascular mortality in liver transplant recipients: a long-term follow-up study 137
Gold standard assays for the monitoring of patients with chronic hepatitis C 136
Endothelial angiopoietin-2 overexpression in explanted livers identifies subjects at higher risk of recurrence of hepatocellular carcinoma after liver transplantation 135
The MELD score in patients awaiting liver transplant: Strengths and weaknesses 134
Nonalcoholic steatohepatitis before and after liver transplant: keeping up with the times 132
Fatty liver index is associated to pulse wave velocity in healthy subjects: Data from the Brisighella Heart Study 129
Allocation priority in non-urgent liver transplantation: An overview of proposed scoring systems 128
Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation 126
The Other Side of Malnutrition in Inflammatory Bowel Disease (IBD): Non-Alcoholic Fatty Liver Disease 126
A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy 126
Surgical site infection prevention and management in immunocompromised patients: a systematic review of the literature 125
Aging with a Liver Graft: Analysis of Very Long-Term Survivors after Liver Transplantation 125
Reproductive Status Is Associated with the Severity of Fibrosis in Women with Hepatitis C 125
Frailty after Liver Transplantation: A Complex Unexplored Issue 124
De-novo nonalcoholic steatohepatitis is associated with long-term increased mortality in liver transplant recipients 124
Non-alcoholic fatty liver disease phenotypes in patients with inflammatory bowel disease article 124
Statin-induced, immune-mediated injury with simultaneous targeting of skeletal muscle, skin and liver 124
Real-world analysis on the use of gamma-hydroxybutyric acid for alcohol withdrawal syndrome in hospitalized patients with diagnosis of cirrhosis 123
The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives 123
Multidisciplinary view of alcohol use disorder: From a psychiatric illness to a major liver disease 122
Liver transplantation from hepatitis B surface antigen positive donors: A safe way to expand the donor pool 122
Metabolic Disorders After Liver Transplantation 122
Stem cells for end stage liver disease: How far have we got? 121
Biological therapies in patients with liver disease: are they really lifesavers? 121
Six score systems to evaluate candidates with advanced cirrhosis for orthotopic liver transplant: Which is the winner? 119
Microbiota and viral hepatitis: State of the art of a complex matter 119
A new prognostic model to predict dropout from the waiting list in cirrhotic candidates for liver transplantation with MELD score <18 118
Non-alcoholic steatohepatitis and liver transplantation 116
Vitamins in the treatment of chronic viral hepatitis 116
Does Metabolic Syndrome and Not the Inflammatory Load Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients? 116
From advanced disease to transplantation: an overview of the liver at the time of COVID-19 pandemic 115
Metabolic Disorders in Liver Transplant Recipients: The State of the Art 114
Acute abdomen in the immunocompromised patient: WSES, SIS-E, WSIS, AAST, and GAIS guidelines 111
Immune Checkpoint Inhibitors in the Pre-Transplant Hepatocellular Carcinoma Setting: A Glimpse Beyond the Liver 110
Familial intrahepatic cholestasis: New and wide perspectives 109
Hepatitis B virus-related cryogobulinemic vasculitis. The role of antiviral nucleot(s)ide analogues: a review 108
Primary biliary cholangitis associated with SARS-CoV-2 infection 107
Acute hepatitis B caused by a vaccine-escape HBV strain in vaccinated subject: Sequence analysis and therapeutic strategy 107
NS5A inhibitors for the treatment of hepatitis C infection 107
Virological Treatment Monitoring for Chronic Hepatitis B 106
Serum hepatitis B surface antigen monitoring in long-term lamivudine-treated hepatitis B virus patients 106
Physical activity in liver transplant recipients: a large multicenter study 105
Menopause, and not age, is a critical factor associated with a worse response to antiviral therapy in women affected by chronic hepatitis C 104
Study of the serum metabolomic profile in nonalcoholic fatty liver disease: Research and clinical perspectives 104
Impact and Novel Perspective of Immune Checkpoint Inhibitors in Patients with Early and Intermediate Stage HCC 103
Impact of psychosocial status on liver transplant process 103
Peginterferon-A-2B plus ribavirin is more effective than peginterferon-A-2A plus ribavirin in menopausal women with chronic hepatitis C 103
Hepatitis C: clinical management and debated issues 103
Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice 102
Worsening of serum lipid profile after direct acting antiviral treatment 102
5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial 99
HBV and HCV testing outcomes among marginalized communities in Italy, 2019–2024: a prospective study 98
Hepatitis C Virus-related chronic liver disease in elderly patients: An Italian cross-sectional study 96
Liver transplantation for patients with alcoholic liver disease: An open question 96
Long term follow-up and outcome of liver transplantation for alcoholic liver disease: A single center case-control study 93
Letter: TNFα inhibitors and prevalence of fatty liver disease in chronic inflammatory diseases 92
Influence of age and gender before and after liver transplantation 91
Liver transplantation and nonalcoholic steatohepatitis: the state of the art 89
Quality of life of hepatitis B virus surface antigen-positive patients with suppressed viral replication: comparison between inactive carriers and nucleot(s)ide analog-treated patients 86
Shunt magnitude is a key determinant of overt hepatic encephalopathy in patients undergoing TIPS 84
Totale 13.865
Categoria #
all - tutte 45.179
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.179


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022413 0 0 58 9 13 5 14 38 40 30 60 146
2022/20231.013 102 287 35 37 25 189 143 48 91 9 30 17
2023/2024515 12 32 89 20 29 53 16 128 15 62 38 21
2024/20253.990 155 398 202 502 1.129 611 187 135 204 100 149 218
2025/20266.394 478 858 722 799 474 246 603 322 388 380 285 839
2026/2027728 306 177 245 0 0 0 0 0 0 0 0 0
Totale 14.454